Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence

PURPOSE: Escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) improves overall survival (OS) in patients with Hodgkin lymphoma (HL) relative to ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) therapy. However, the associated h...

Descripción completa

Detalles Bibliográficos
Autores principales: Seshachalam, Arun, Karpurmath, Shashidhar V., Rathnam, Krishnakumar, Raman, S. Ganapathi, Janarthinakani, Murugesan, Prasad, Krishna, Patil, Channappa, Anoop, Parameswaran, Reddy, Neelesh, Anumula, Satish Kumar, Roopa, Sirigeri Prabhakar, Golamari, Krishna Reddy, Danthala, Madhav, Gunari, Prasad, Malipatil, Basawantrao, Rangarajan, Bharath, Udupa, Karthik S., Nandennavar, Manjunath, Niraimathi, Kesavan, Shewade, Hemant Deepak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939745/
https://www.ncbi.nlm.nih.gov/pubmed/31834832
http://dx.doi.org/10.1200/JGO.19.00179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939745/
https://www.ncbi.nlm.nih.gov/pubmed/31834832
http://dx.doi.org/10.1200/JGO.19.00179

Ejemplares similares